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Abstract
Background: Mild hypothermia is currently standard of care for cardiac arrest patients in many
hospitals and a common belief is that hypothermia attenuates platelet aggregation. We wanted to
examine the effects of clopidogrel on platelet aggregation during hypothermia.
Methods: Platelet reactivity at 37°C and 33°C was evaluated by light transmission aggregometry
and vasodilator-stimulated phosphoprotein (VASP) in blood from healthy volunteers before, and
24 hours after, a 600 mg loading dose of clopidogrel.
Results:  Collagen, 5-HT, epinephrine, U46619 and ADP-induced platelet aggregation was
unaltered or even increased by hypothermia. After clopidogrel, there was a significant increase in
platelet aggregation for 5 and 20 μM ADP at 33°C compared to 37°C (46 ± 5 vs. 34 ± 5% and 58
± 4 vs. 47 ± 4%, p < 0.001, n = 8). Hypothermia also increased ADP-induced aggregation after
pretreatment with the P2Y1 antagonist MRS2500. The decreased responsiveness to clopidogrel
during hypothermia could be overcome by addition of the reversible P2Y12 antagonist AZD6140.
ADP-induced inhibition of VASP-phosphorylation was unaffected by hypothermia both in the
presence and absence of clopidogrel. A dose-response curve for ADP-induced platelet aggregation
revealed increased potency for ADP during hypothermia with no difference in efficacy.
Conclusion: Mild hypothermia did not attenuate platelet aggregation, instead it even increased
ADP-stimulated platelet aggregation after clopidogrel treatment. Dual platelet inhibition with
aspirin and a P2Y12 receptor antagonist is probably needed for patients with acute coronary
syndromes treated with mild hypothermia, and it is possible that future ADP blockers could be of
benefit.
Introduction
Hypothermia is a condition in which many biological
reactions are altered. Even a minor change of temperature
in a cell can alter the response to stimuli. Mild hypother-
mia (33–35°C) has been shown to reduce mortality and
improve neurological outcome in unconscious patients
with cardiac arrest [1,2], and is recommended by treat-
ment guidelines [3]. Mild hypothermia is already stand-
ard of care in many hospitals for cardiac arrest patients.
Furthermore, mild hypothermia has been shown to
reduce myocardial infarct size in animal models, and clin-
ical studies are ongoing to determine whether this strategy
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can preserve not only the brain but also the heart [4]. For
many patients with cardiac arrest, the aetiology is an acute
coronary syndrome, which needs to be treated with plate-
let inhibitors. The cornerstone of this treatment is dual
antiplatelet therapy with aspirin and clopidogrel [3].
However, to our knowledge, the pharmacodynamic
effects of clopidogrel during hypothermia have never
been studied.
Conventional wisdom holds that hypothermia reduces
platelet activation, and it has been suggested that
antiplatelet treatment should be reduced during hypo-
thermia. There are some studies supporting this notion [5-
7]. However, there are more recent reports suggesting
increased platelet reactivity during mild hypothermia [8-
11]. It is of great importance to select the correct level of
platelet inhibition for this patient category. Insufficient
platelet inhibition may result in stent thrombosis, acute
myocardial infarction, and cardiac death. It is therefore
important to understand the effect of hypothermia on
clopidogrel treatment.
To examine the effect of clopidogrel during mild hypo-
thermia, we analyzed platelet reactivity as measured by
light transmission aggregometry (LTA), vasodilator-stim-
ulated phosphoprotein (VASP)-phosphorylation, and a
P2Y12 specific flow cytometry assay, in healthy volunteers
at 37° and 33°C before and 24 hours after a 600 mg dose
of clopidogrel.
Materials and methods
Platelet preparation for LTA analysis
Whole blood samples (40 mL) were collected from
healthy voluntary blood donors (n = 8). The blood sam-
ples were collected from an antecubital vein into Becton
Dickinson (BD) Vacutainer™ tubes containing 0.129 M
sodium citrate. A second blood sample was collected 24
hours after a 600 mg oral loading dose of clopidogrel. To
obtain platelet rich plasma (PRP), whole blood was cen-
trifuged (10 min, 140 × g, room temperature (RT)). After
centrifugation the supernatant containing the PRP was
collected and transferred to a 15 mL polypropylene tube.
To obtain reference platelet poor plasma (PPP), whole
blood was centrifuged (10 min, 2260 × g, RT). The super-
natant containing PPP was collected into a 15 mL poly-
propylene tube.
LTA analyses
Two serial connected aggregometers (Chrono-Log 490,
Chrono-Log Corporation, Havertown, PA, USA) were pre-
heated to 37°C and 33°C respectively. To allow for tem-
perature equilibration, the PRP was incubated for 5
minutes in the aggregometers prior to addition of an ago-
nist. In experiments with ex vivo antagonists, addition of
these compounds was followed by incubation for 5 min
prior to ADP stimulation. Analyses were performed using
AGGRO/LINK®  software (Chrono-Log Corporation,
Havertown, PA, USA.). Stirring was set to 1200 rpm and
the optical band was in the range of 600 OD. Each of the
experiments continued for 6 minutes (to observe if a sec-
ondary aggregation took place). The test volumes contain-
ing PRP were set to 250 μL, while the PPP volume in the
reference wells of the two aggregometers was set to 500
μL.
Flow cytometric analysis of VASP-phosphorylation
Whole blood was collected from the antecubital vein into
BD Vacutainer™ tubes containing 0.129 M sodium citrate.
The blood was incubated for 10 min at 33°C and 37°C.
The VASP assay was performed using the platelet VASP/
P2Y12 kit (Biocytex Platelet VASP kit, Marseille, FR). The
experimental procedure was carried out according to the
manufacturer's instructions except that the samples were
prepared at 33°C and 37°C instead of room temperature
until the fixation step. Mean Fluorescence Intensity (MFI)
was measured with a flow cytometer (FACScalibur®, BD,
USA). Platelet reactivity index (PRI) was calculated from
the corrected MFI (cMFI) of prostaglandin E1 (PGE1) and
ADP- and PGE1- treated samples according to the follow-
ing equation:
PRI = [(cMFI(PGE1) - cMFI(PGE1+ADP))/cMFI(PGE1)] × 100
Drugs
ADP, epinephrine, collagen, and thrombin were from
Chrono-Log Corporation, USA. AZD6140 was a gift from
Astra-Zeneca, Sweden. MRS2500 was from Tocris Bio-
science, UK. U-46619 was from Sigma-Aldrich, USA.
Clopidogrel was from Sanofi Pharma Bristol-Myers
Squibb SNC, France. All drugs (clopidogrel excluded)
were dissolved in 0.9% saline; AZD6140 was dissolved in
DMSO at 10-2 M and then further diluted in 0.9% saline.
Ethics
The Ethics Committee of Lund University approved the
project. All blood donors provided signed informed con-
sent to participate in the study.
Calculation and statistics
Statistical analyses were performed using the GraphPad
Prism 4.0 software (Graph Pad Software, USA). LTA and
VASP data were analyzed using paired Student's t-test. P-
values less than 0.05 were regarded as statistically signifi-
cant. Values are presented as mean ± s.e.m.
Results
ADP-stimulated platelet aggregation evaluated by LTA
There was no significant difference in maximum platelet
aggregation (MPA) levels when PRP was stimulated with
5 μM ADP at 33°C compared to 37°C (79 ± 1 vs. 80 ± 1%,Thrombosis Journal 2009, 7:2 http://www.thrombosisjournal.com/content/7/1/2
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P = NS, n = 8) or with 20 μM ADP at 33°C compared to
37°C (80 ± 2 vs. 80 ± 1%, P = NS, n = 8) [Figure 1a, b].
ADP-stimulated platelet aggregation before and after 
clopidogrel treatment
24 hours after a loading dose of 600 mg clopidogrel, there
was a significant increase in MPA after both 5 and 20 μM
ADP at 33°C compared to 37°C (46 ± 5 vs. 34 ± 5%, P <
0.001, n = 8, and 58 ± 4 vs. 47 ± 4%, P < 0.001, n = 8) [Fig-
ure 1c, d]. There was a significant increase in MPA when
PRP treated with the P2Y1 receptor antagonist MRS2500
(1 μM) was stimulated with 5 μM ADP at 33°C compared
to 37°C (57 ± 7 vs. 41 ± 9%, P < 0.05, n = 8) [Figure 2a]
and with combined treatment with oral clopidogrel and
MRS2500 ex vivo (15 ± 4 vs. 7 ± 3%, P < 0.001, n = 8) [Fig-
ure 2b]. 10 μM AZD6140 ex vivo in addition to per oral
clopidogrelmarkedly reduced MPA after 5 μM ADP with
no significant difference in MPA at 33°C compared to
37°C [Figure 2c].
Collagen-, 5-HT-, epinephrine-, and U46619-stimulated 
platelet aggregation before and after clopidogrel 
treatment
There was no significant difference in MPA when PRP was
stimulated with 2 μg/ml collagen without clopidogrel at
33°C compared to 37°C (79 ± 1 vs. 83 ± 2%, P = NS, n =
8) or after oral clopidogrel (71 ± 5 vs 71 ± 4%, P = NS, n
= 8) [Figure 3a, b]. There was a significant increase in MPA
levels with 10 μM 5-HT at 33°C compared to 37°C both
without clopidogrel (9.5 ± 1.5 vs. 6.3 ± 1.8%, P < 0.001, n
= 8) and after oral clopidogrel (9.6 ± 2.4 vs. 6.0 ± 2.2%, P
< 0.001, n = 8) [Figure 3c, d]. No differences in MPA
between temperatures were observed with epinephrine 10
μM without clopidogrel (73 ± 6 vs 69 ± 7%, P = NS, n = 8)
or after clopidogrel (61 ± 8 vs. 62 ± 7%, P = NS., n = 8)
[Figure 4a, b] or with U46619 10 μM without clopidogrel
(27 ± 14 vs 38 ± 14%, P = NS, n = 8) or after clopidogrel
(15 ± 5 vs. 11 ± 4%, P = NS, n = 8) [Figure 4c, d].
Inhibition of P2Y12 receptors evaluated by VASP-
phosphorylation
PRI (%) as assessed by the VASP kit was similar at 33°C
compared to 37°C at baseline (71 ± 3 vs. 65 ± 7%, P = NS,
n = 8) and after a 600 mg loading dose of clopidogrel (30
± 7 vs. 27 ± 5%, P = NS, n = 8) [Figure 5a, b]. PRI (%) VASP
was also similar at 33°C compared to 37°C with ADP and
10 μM AZD6140 added ex vivo [Figure 5c].
Dose response for ADP-stimulated platelet aggregation 
evaluated by LTA
To further evaluate the mechanism of increased sensitivity
to ADP during hypothermia, we performed a narrow dose
response curve for ADP-induced platelet aggregation in a
new subset of healthy individuals. There was no signifi-
cant increase in the plateau phase of MPA at 33°C com-
pared to 37°C, 72.0% (95% confidence interval (CI)
66.9–77.2) vs 77.8%, CI 66.9–88.6), P = NS, n = 7) [Fig-
ure 6]. However, there was leftward shift of the dose
response curve indicating increased potency for ADP dur-
ing hypothermia (EC50 = 0.68 μM (confidence interval
0.41–0.93)) compared to normothermia (EC50 = 1.38 μM
(confidence interval 1.06–1.70)). MPA was significantly
higher during hypothermia for 0.5, 1.0, and 1.5 μM of
ADP.
Discussion
We examined platelet reactivity before and after clopidog-
rel treatment at 37°C and at 33°C, a temperature used for
the treatment of patients resuscitated after cardiac arrest.
Mild hypothermia did not attenuate platelet aggregation.
Instead, collagen, 5-HT, epinephrine, the thromboxane
analogue U46619 and ADP-induced platelet aggregation
was unaltered or even increased by hypothermia. Dose-
response curves revealed increased potency of ADP during
hypothermia with no change in efficacy (maximum
effect) compared with normothermia. Furthermore, the
inhibitory effect of clopidogrel was attenuated. Similar
attenuation of effect on ADP-induced aggregation was
also seen after inhibition with the P2Y1  antagonist
MRS2500. The decreased responsiveness to clopidogrel
during hypothermia could be overcome by addition of
the P2Y12 antagonist AZD6140.
Dual antiplatelet therapy with aspirin and clopidogrel is
recommended treatment for patients with acute coronary
syndromes and after stent implantation [3]. A more rapid
onset and higher level of platelet inhibition can be
obtained with a 600 mg loading dose of clopidogrel, a
dose recently endorsed for acute coronary syndromes to
obtain better protection during percutaneous coronary
interventions. A large number of patients with cardiac
arrest have an acute coronary syndrome; some of them are
treated with direct-PCI and stenting because of ST-eleva-
tion myocardial infarction, and therefore receive clopi-
dogrel treatment. Despite this, the effect of clopidogrel
has to our knowledge never been examined during mild
hypothermia.
There is a general belief that mild hypothermia attenuates
platelet aggregation [6,12], and it was somewhat surpris-
ing to find that collagen, 5-HT, epinephrine, the throm-
boxane analogue U46619 and ADP-stimulated platelet
aggregation was unaltered or even increased by mild
hypothermia. Most of the previous studies have been per-
formed at lower temperatures, eg, 28°, 22°, or even 2°C
[6,7,13]. Our interest was in the growing use of mild
hypothermia (33–35°C) for the treatment of cardiac
arrest, and perhaps in the future to reduce infarct size in
patients with acute myocardial infarction. One study
demonstrated a reduction in ADP-stimulated plateletThrombosis Journal 2009, 7:2 http://www.thrombosisjournal.com/content/7/1/2
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ADP-stimulated platelet aggregation at 5 and 20 μM [a, b] and after treatment with clopidogrel (600 mg) po [c, d] Figure 1
ADP-stimulated platelet aggregation at 5 and 20 μM [a, b] and after treatment with clopidogrel (600 mg) po 
[c, d]. n = 8. filled symbols represents normothermia (37°), open symbols represents hypothermia (33°), n.s. = not significant, 
*** = P < 0.001.
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aggregation by 16% at 32°C compared to 37°C [5]. In
contrast, a recent study by Heptinstall et al. demonstrated
increased ADP-stimulated platelet aggregation at 28°C [9].
Lindenblatt et al[8] found increased ex vivo stimulated
GpIIb/IIIa expression after TRAP stimulation at 34°C
compared to normothermia, as well as accelerated throm-
bus formation in vivo in mice at 34°C. Our findings are
also in agreement with Scharbert and co-workers[10],
who found that platelet aggregation was increased with
ADP, but unaltered with collagen during hypothermia.
Further, shear stress-induced aggregation has been shown
to increase at 32°C and 35°C[11].
In the present study, we found an attenuated effect of
clopidogrel on ADP-stimulated platelet aggregation dur-
ing mild hypothermia. The effect was highly significant
and consistent at both doses of ADP used. This is in agree-
ment with previous studies that have shown increased
ADP responses during hypothermia in the presence of
aspirin[9,10]. However, mild hypothermia has also been
shown to augment the inhibitory effect of the reversible
GpIIb/IIIa-blockers eptifibatide and tirofiban (but not
that of the irreversible blocker abciximab)[5]. It could be
hypothesized that hypothermia affects different classes of
platelet inhibitors differently. Such information is of
course important in the selection of adequate platelet
inhibition for patients treated with mild hypothermia.
Since the first report of a variable response to clopidogrel
[14], a large number of studies have found a high preva-
lence of patients with pharmacodynamic poor responsive-
ness to clopidogrel [15]. Our data indicate that
hypothermia induces a situation in which the effect of
clopidogrel is reduced. The decreased responsiveness to
clopidogrel during hypothermia could be overcome by
addition of the reversible P2Y12 antagonist AZD6140.
ADP activates two receptors on the platelet: the Gi-cou-
pled P2Y12 receptor coupled to inhibition of cAMP; and
the Gq-coupled P2Y1 receptor, which stimulates IP3 and
increases intracellular Ca2+. We tried to elucidate the
mechanisms of the platelet effects induced by hypother-
mia by testing whether they were P2Y12-specific. We
added the selective P2Y1-receptor antagonist MRS2500.
Even in this situation, increased ADP sensitivity was seen
during mild hypothermia. The effect was even more pro-
nounced when MRS2500 was combined with clopidogrel.
ADP (5 μM) -stimulated platelet aggregation after pretreatment with MRS2500 (1 μM) ex vivo [a], after pretreatment with  clopidogrel (600 mg) po and MRS2500 ex vivo [b], and after pretreatment with clopidogrel (600 mg) po and AZD6140 (10 μM)  ex vivo [c] Figure 2
ADP (5 μM) -stimulated platelet aggregation after pretreatment with MRS2500 (1 μM) ex vivo [a], after pre-
treatment with clopidogrel (600 mg) po and MRS2500 ex vivo [b], and after pretreatment with clopidogrel 
(600 mg) po and AZD6140 (10 μM) ex vivo [c]. n = 8. Filled symbols represents normothermia (37°), open symbols rep-
resents hypothermia (33°), n.s. = not significant, * = P < 0.05, *** = P < 0.001.Thrombosis Journal 2009, 7:2 http://www.thrombosisjournal.com/content/7/1/2
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Platelet aggregation stimulated by collagen (2 μg/ml) [a, b] and by 5-HT (10 μM) [c, d] before and after pretreatement with  clopidogrel (600 mg) po Figure 3
Platelet aggregation stimulated by collagen (2 μg/ml) [a, b] and by 5-HT (10 μM) [c, d] before and after pre-
treatement with clopidogrel (600 mg) po. n = 8. Filled symbols represents normothermia (37°), open symbols represents 
hypothermia (33°), n.s. = not significant, *** = p < 0.001.
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Platelet aggregation stimulated by epinephrine (10 μM) [a, b] and U46619 (10 μM) [c, d] before and after pretreatement with  clopidogrel (600 mg) po Figure 4
Platelet aggregation stimulated by epinephrine (10 μM) [a, b] and U46619 (10 μM) [c, d] before and after pre-
treatement with clopidogrel (600 mg) po. N = 6–8. Filled symbols represents normothermia (37°), open symbols repre-
sents hypothermia (33°), n.s. = not significant.
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Thus, the increased platelet stimulatory effect of ADP can
be seen regardless of which ADP receptor is blocked.
ADP activation of the P2Y12 receptor results in reduction
of cAMP. VASP is an intracellular actin regulatory protein
[16,17] that is phosphorylated into its P-VASP form by
cAMP dependent protein kinases. ADP, the natural ago-
nist to the P2Y12 receptor, inhibits VASP phosphorylation
through inhibition of adenylate cyclase and downregula-
tion of cAMP production. We examined if the mechanism
of the platelet effects of hypothermia are mediated at the
level of VASP-phosphorylation. However, we saw no
effect of hypothermia on VASP-phosphorylation when
whole blood was stimulated by ADP alone or in combina-
tion with clopidogrel or AZD6140.
The mechanism of the increased ADP-induced platelet
aggregation during hypothermia observed in our study
remains elusive. It does not seem to depend on antago-
nist-receptor interaction or intracellular second messen-
ger systems. Another possible explanation would be
altered degradation rates of ADP. However, we repeated
the experiments with the stable ADP analogue 2-MeSADP
and obtained similar results (data not shown). To under-
stand the receptor pharmacology during hypothermia, we
assessed dose-response curves for ADP. Platelets at 33°C
displayed an increased sensitivity to ADP and epinephrine
compared to 37°C, with a leftward shift of the dose-
response curve and a significantly lower EC50 value for
platelets at 33°C. Thus, it was only possible to see a differ-
ence in effect when doses in the sigmoidal part of the
curve were tested, with the maximum effect being unal-
tered compared with normothermia. This observation
may explain some of the conflicting data in the literature.
It also indicates that it is important to take the concentra-
tion of the agonist into consideration when studying
hypothermia and platelets.
Haemostasis during hypothermia is complex, and it is
possible that platelet responses differ at different temper-
atures. We found unaltered or even increased platelet
Figure 5
A
C
B
Flow cytometry study in which phosphorylation of VASP  (and hence inhibition of platelet activation) is stimulated by  PGE1 and dephosphorylation (and hence augmentation of  platelet activation) is mediated by ADP Figure 5
Flow cytometry study in which phosphorylation of 
VASP (and hence inhibition of platelet activation) is 
stimulated by PGE1 and dephosphorylation (and 
hence augmentation of platelet activation) is medi-
ated by ADP. Platelet activation is represented as platelet 
reactivity index (%PRI). ADP-stimulated platelet aggregation 
at baseline [a], after pretreatment with clopidogrel po [b], 
and after pretreatment with AZD6140 (10 μM) ex vivo [c]. n 
= 8. Filled symbols represents normothermia (37°), open 
symbols represents hypothermia (33°), n.s. = not significant.Thrombosis Journal 2009, 7:2 http://www.thrombosisjournal.com/content/7/1/2
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responses during mild hypothermia. The literature con-
tains conflicting data, but in support of our findings,
increased platelet activation has been seen during pro-
found hypothermia[13] and increased aggregation has
been reported at a more intermediate temperature of
28°C [9]. However, prolongation of bleeding time has
been reported in clinical situations with hypothermia [18-
20]. It is possible that this primarily reflects effects of
hypothermia on the coagulation system, especially a
decrease in the fibrinolysis-inhibiting α2-macroglobulin
levels [21]. On the other hand, unintentional periopera-
tive hypothermia is associated with postoperative myocar-
dial ischemia, indicating a prothrombotic effect of
hypothermia, and platelet count and platelet activity have
been shown to be increased in this setting [12,21].
Conclusion
In conclusion, our study indicates that platelet reactivity is
unaltered and in some situations increased during mild
hypothermia. The inhibitory effect of clopidogrel was
attenuated in our study. The clinical conclusion is that we
cannot rely on hypothermia per se as a platelet inhibitor.
Based on current ex vivo evidence, dual platelet inhibition
with aspirin and clopidogrel is probably needed for
patients with acute coronary syndromes treated with mild
hypothermia. Since hypothermia induces a state of
reduced clopidogrel responsiveness, it is possible that new
reversible ADP blockers such as AZD6140 could be bene-
ficial. Clinical studies are needed to determine the best use
of platelet and coagulation inhibitors for the growing
number of patients treated with mild hypothermia.
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